文献速递类风湿关节炎

类风湿关节炎非严重感染:英国风湿病学会生物制剂注册研究结果

Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2021-08-17

该研究基于BSRBR-RA前瞻性队列,描述类风湿关节炎患者非严重感染(NSI)的频率与预测因素,并比较不同生物制剂间的NSI风险。8,145例患者共发生17,304次NSI,事件率为27.0/人年(95%CI 26.6-27.4);与TNFi相比,IL-6抑制剂和利妥昔单抗的NSI风险更高,而csDMARDs单药风险更低。

要点

  • RA患者NSI事件率为27.0/人年(95%CI 26.6-27.4),发生频繁
  • 与TNFi相比,IL-6抑制剂和利妥昔单抗的NSI风险更高
  • csDMARDs单药较生物制剂NSI风险更低,阿达木单抗高于依那西普

核心结论

  • NSI在RA中频繁发生,其预测因素与严重感染报道的相似。
  • 所有生物制剂均与更高的NSI风险相关,且药物间存在差异。
  • 尽管需考虑未测量混杂,但效应量大,NSI与靶向免疫调节治疗之间可能存在关联。

研究设计与样本

  • BSRBR-RA为前瞻性观察性队列研究。
  • NSI定义为不需住院或静脉治疗的感染,通过临床医生问卷和患者日记捕获。
  • 个体从启动生物制剂治疗起视为「 at risk」长达3年,药物暴露按TNFi、IL-6抑制剂、B细胞清除(利妥昔单抗)或csDMARDs单药定义。
  • 采用多重失败Cox模型进行多变量调整,缺失数据用多重插补处理。

主要发现

  • 8,145例患者共发生17,304次NSI,事件率为27.0/人年(95%CI 26.6-27.4)。
  • 年龄增加、女性、合并症负担、糖皮质激素治疗、更高的DAS28和更高的HAQ残疾指数与NSI风险增加相关。
  • 与生物制剂相比,csDMARDs显著降低NSI风险。
  • 与TNFi相比,IL-6抑制和利妥昔单抗与更高的NSI风险相关(调整HR 1.45 [95%CI 1.29-1.63] 和调整HR 1.28 [95%CI 1.14-1.45]),而csDMARDs队列风险更低(调整HR 0.64 [95%CI 0.59-0.70])。
  • 在TNFi类别内,阿达木单抗较依那西普与更高的NSI风险相关(调整HR 1.11 [95%CI 1.05-1.17])。

临床怎么用

  • 临床中应关注RA患者NSI的预测因素,如年龄、女性、合并症、糖皮质激素使用、高疾病活动度和残疾指数。
  • 选择生物制剂时需考虑不同药物间NSI风险的差异,IL-6抑制剂和利妥昔单抗的NSI风险高于TNFi。
  • csDMARDs单药治疗的NSI风险低于生物制剂,在适当患者中可作为选择。
  • TNFi类别内,阿达木单抗的NSI风险高于依那西普。

局限性

  • 研究为观察性设计,存在未测量混杂的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the frequency and predictors of nonserious infections (NSI) and compare incidence across biologic agents within the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). METHODS: The BSRBR-RA is a prospective observational cohort study. An NSI was defined as an infection that did not require hospitalization or intravenous therapy. Infections were captured from clinician questionnaires and patient diaries. Individuals were considered "at risk" from the date of initiation of biologic treatment for up to 3 years. Drug exposure was defined by agent: tumor necrosis factor inhibitor (TNFi), interleukin-6 (IL-6) inhibitor, B cell depletion (rituximab), or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) alone. A multiple-failure Cox model was used with multivariable adjustment. Missing data were addressed using multiple imputation. RESULTS: There were 17,304 NSI in 8,145 patients, with an event rate of 27.0 per person per year (95% confidence interval [95% CI] 26.6-27.4). Increasing age, female sex, comorbidity burden, glucocorticoid therapy, higher Disease Activity Score in 28 joints, and higher Health Assessment Questionnaire disability index were associated with an increased risk of NSI. There was a significant reduction in NSI risk with csDMARDs compared to biologic treatments. Compared to TNFi, IL-6 inhibition and rituximab were associated with a higher NSI risk (adjusted hazard ratio 1.45 [95% CI 1.29-1.63] and adjusted hazard ratio 1.28 [95% CI 1.14-1.45], respectively), while the csDMARD cohort had a lower risk (adjusted hazard ratio 0.64 [95% CI 0.59-0.70]). Within the TNFi class, adalimumab was associated with a higher NSI risk than etanercept (adjusted hazard ratio 1.11 [95% CI 1.05-1.17]). CONCLUSION: NSI occur frequently in RA, and predictors mirror those reported with serious infections. All biologics are associated with a greater risk of NSI, with differences observed between agents. While unmeasured confounding must be considered, the magnitude of effect is large, and a relationship between NSI and targeted immunomodulatory therapy likely exists.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bechman K, Halai K, Yates M, et al. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis Rheumatol. 2021. PMID: 33844458. doi:10.1002/art.41754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。